Osugacestat (AL101, BMS-906024)
ACCURACY
Ayala Pharmaceuticals · Phase 2 · Completed · Enrollment 87
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| AL101 4 mg | R/M ACC with NOTCH1 to 4 activating mutation (n = 45) | 4 mg | Single arm | n/r | responders (CR or PR): 3 patients (of 45), final, results posted 01.31.2024median overall survival: 9.3 months, final |
| AL101 6 mg | R/M ACC with NOTCH activating mutation (n = 42) | 6 mg | Single arm | n/r | responders (CR or PR): 2 patients (of 42), finalmedian overall survival: 9.4 months, final |